Geom Therapeutics

About:

Geom Therapeutics is a biotechnology company.

Website: https://www.geomtherapeutics.com/

Top Investors: Sears Capital Management

Description:

Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, their lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.

Total Funding Amount:

$4.36M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2015-12-22

Founders:

Brendan Hannah

Number of Employees:

1-10

Last Funding Date:

2017-04-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai